CCDC92: A Potential Drug Target and Biomarker (G80212)

Target Name: CCDC92

NCBI ID: G80212

CCDC92

CCDC92: A Potential Drug Target and Biomarker

CDC92 (Coiled-coil domain containing 92) is a protein that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in various cellular processes, including cell division, migration, and invasion. The CCDC92 gene has four isoforms, which are responsible for the four distinct stages of the cell cycle. The CCDC92 protein plays a crucial role in the regulation of the mitotic checkpoint, which ensures that each cell has the correct number of chromosomes before entering mitosis.

CDC92 is a protein that is expressed in a variety of tissues and cells, including brain, pancreas, and cancer cells. It is also highly expressed in the placenta, which supports the idea that it may be a potential biomarker for various diseases, including cancer.

CDC92 as a Drug Target

The CCDC92 protein is a good candidate for a drug target due to its unique structure and its involvement in various cellular processes. One of the main reasons for its potential as a drug target is its ability to interact with various signaling pathways. It has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, the TGF-灏? signaling pathway, and the Wnt signaling pathway.

The PI3K/Akt signaling pathway is a well-established signaling pathway that is involved in various cellular processes, including cell survival, angiogenesis, and inflammation. CCDC92 has been shown to interact with the p110浼? subunit of the PI3K/Akt signaling pathway, which suggests that it may be a potential drug target for the treatment of various diseases, including cancer.

The TGF-灏? signaling pathway is a signaling pathway that is involved in cell growth, differentiation, and survival. CCDC92 has been shown to interact with the transforming growth factor beta-1 (TGF-灏?1) receptor, which suggests that it may be a potential drug target for the treatment of various diseases, including cancer.

The Wnt signaling pathway is a signaling pathway that is involved in cell growth, differentiation, and development. CCDC92 has been shown to interact with the Wnt receptor, which suggests that it may be a potential drug target for the treatment of various diseases, including cancer.

CDC92 as a Biomarker

CDC92 has also been identified as a potential biomarker for various diseases, including cancer. The CCDC92 protein is highly expressed in various tissues and cells, including cancer cells. It has also been shown to be downregulated in various types of cancer, which suggests that it may be a potential biomarker for the diagnosis and monitoring of cancer.

In addition to its potential as a drug target, CCDC92 has also been identified as a potential biomarker for various diseases, including cancer. The CCDC92 protein is highly expressed in various tissues and cells, including cancer cells. It has also been shown to be downregulated in various types of cancer, which suggests that it may be a potential biomarker for the diagnosis and monitoring of cancer.

Conclusion

In conclusion, CCDC92 is a protein that has been identified as a potential drug target and biomarker. Its unique structure and involvement in various cellular processes make it a promising candidate for drug development. Further research is needed to fully understand the role of CCDC92 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Coiled-coil Domain Containing 92

Functions: Interferon-stimulated protein that plays a role in innate immunity. Strongly inhibits ebolavirus transcription and replication. Forms a complex with viral RNA-bound nucleocapsid NP and thereby prevents the transport of NP to the cell surface

The "CCDC92 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC92 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets